Introduction {#s1}
============

Development of an organism from a fertilized egg involves the coordination of cell lineage specification coupled with the establishment of cardinal axes (including the anterior-posterior (A-P) axis), to build a blueprint for the body plan ([@bib3]). The earliest stages of mammalian development culminate in the formation of a blastocyst comprising three cell lineages: the pluripotent epiblast (Epi) which gives rise to somatic and germ cells, and two extra-embryonic lineages, the primitive endoderm (PrE) and trophectoderm (TE) ([@bib53]). Mouse embryonic stem cells (ESCs) are derived from, and represent an in vitro self-renewing counterpart of, the so-called 'naive' pluripotent epiblast cells of the blastocyst ([@bib45]; [@bib10]). Pluripotency comprises a continuum of states sequentially encompassing naive, formative and ultimately primed pluripotency ([@bib57]). Upon blastocyst implantation into the maternal uterus, epiblast cells acquire characteristics of the more developmentally advanced formative and then primed states of pluripotency, which are represented by epiblast-like cells (EpiLCs) ([@bib33]) and epiblast stem cells (EpiSCs) ([@bib13]; [@bib61]; [@bib39]), respectively. Exploiting the ability of ESCs to transition into EpiLCs/EpiSCs has advanced the mechanistic understanding of epiblast maturation. However, while in vitro studies are instrumental, it remains critical to confirm whether the insights they provide are relevant to events taking place in vivo where the only *bona fide* pluripotent population, the epiblast, normally exists. The transition to more developmentally advanced states of pluripotency occurs in the mouse embryo coincident with its implantation into the maternal uterus, at around embryonic day (E)4.5--5.0, and is marked by several stereotypical morphological and molecular changes ([@bib5]). Acquisition of the primed state of pluripotency precedes the onset of gastrulation (at E6.25), the process in which the three embryonic germ layers - ectoderm, mesoderm, and endoderm - are formed ([@bib60]; [@bib3]; [@bib59]).

Key events of epiblast maturation include coordinated expression of specific transcription factors (TFs) across developmental stages. Nanog, Klf4, and Rex1 (also named Zfp42) are highly expressed in the epiblast of the blastocyst and ESCs, whereas Fgf5, Oct6 (also named Pou3f1), and Otx2 are upregulated in the epiblast following embryo implantation, or when ESCs differentiate toward EpiSCs. Factors such as Eomes or T (also named Brachyury) are expressed in gastrulating embryos at the primitive streak (the site where pluripotent cells undergo lineage differentiation) and in EpiSCs. Other pluripotency-associated TFs, such as Oct4, Sox2, and Zfp281, are expressed in the pluripotent epiblast throughout these state transitions, suggesting they may play distinct roles in different pluripotent states, or enable transitions between them. Specific DNA modifications and reorganization of enhancer landscapes also occur during the naive-to-primed transition, together with genome-wide relocation of Oct4, as well as elevated binding of Otx2 and the P300 histone acetyltransferase at enhancers of genes specific to the primed state ([@bib14]; [@bib70]). Concomitantly, during early post-implantation embryo development, the A-P axis is established. A-P patterning is not readily recapitulated in ESC or EpiSC cultures since it necessitates cross-talk between the epiblast and its adjacent extra-embryonic tissue, the visceral endoderm (VE) ([@bib55]). In the mouse embryo, distal visceral endoderm (DVE) cells, specified at the late blastocyst stage as a sub-population of the PrE, are critical for A-P axis establishment ([@bib4]; [@bib59]). At E5.5, DVE cells are localized at the distal tip of the embryo from where they migrate proximally towards the extra-embryonic/embryonic boundary, recruiting a second population (the anterior visceral endoderm or AVE) and defining an anterior to the embryo, thereby establishing an A-P axis ([@bib58]). The TGF-beta ligand Nodal, which is expressed by the epiblast, and several of its pathway components, such as the left-right determination factors (Lefty1 and 2) ([@bib12]), Cripto (also named Tdgf1) ([@bib23]), and Foxh1 ([@bib69]) are required for DVE/AVE specification, migration, and A-P axis formation ([@bib13]; [@bib59]). Whether epiblast maturation and A-P axis specification can be mechanistically linked remains an open question.

Zfp281 was recently identified as a TF required for the commitment of ESCs to differentiation in culture ([@bib9]; [@bib29]). In this study, we investigate pluripotent state transitions in vivo in their native context, and identify a key role for Zfp281 in early mammalian development. Mouse embryos lacking Zfp281 reach the blastocyst stage and establish a pluripotent epiblast lineage. However, they exhibit defects in epiblast maturation, indicated by the failure to robustly activate Nodal signaling and genes associated with the primed pluripotent state. Hence, they are unable to exit the naive pluripotent state, resulting in a failure to establish an A-P axis. Mechanistically, we demonstrate that Zfp281 functions specifically within the epiblast to coordinate the epigenetic regulators acting to initiate expression of lineage-specific genes and modulate the Nodal signaling pathway.

Results {#s2}
=======

Zfp281 is expressed in early mouse embryos and required for early post-implantation development {#s2-1}
-----------------------------------------------------------------------------------------------

To begin to investigate the role of Zfp281 in vivo during mouse embryonic development when the pluripotent epiblast population is established and matures, we determined the localization of the Zfp281 protein by immunohistochemistry ([Figure 1A--C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). At E3.5, representing the mid-blastocyst stage, Zfp281 was nuclear-localized and detected at low levels throughout the inner cell mass (ICM) and trophectoderm (TE) ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). This widespread expression was maintained until the late blastocyst stage (E4.5) in both ICM derivatives including Epi and PrE, as well as the TE ([Figure 1A--B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Single-cell quantitative immunofluorescence ([@bib41]; [@bib52]) and single-cell microarray data ([@bib47]) revealed that Zfp281 expression was elevated in the epiblast of late stage blastocysts ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). At later (post-implantation) stages, Zfp281 expression was restricted to the epiblast and its derivatives ([Figure 1A](#fig1){ref-type="fig"}) and absent from the visceral endoderm (VE), a squamous epithelium derived from the PrE, which encapsulates the epiblast ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

![Zfp281 is expressed in the pluripotent epiblast and is required for early post-implantation embryo development.\
(**A**) Single optical sections depicting Zfp281 protein expression in pre- and post-implantation. At pre-implantation, nuclear-localized Zfp281 protein is observed in epiblast (Epi), primitive endoderm (PrE) and trophectoderm (TE) cells, as quantified in (**B**). Zfp281 expression is specific to epiblast at post-implantation (E5.75), quantified in (**B**). Immunohistochemistry of *Zfp281*KO embryo at E5.75 shows that the protein is not expressed, confirming the mutant as a protein null. It also reveals VE-specific background. High-magnification insets (top-right) show protein distribution in regions highlighted, white dashed lines delimit the VE layer. At onset of gastrulation (E6.5), Zfp281 is expressed in all epiblast-derived cells. (**B**) Quantification of nuclear levels of Zfp281 using MINS software at mid- (E3.5) and late (E4.25--4.5) blastocyst stage, revealing protein expression in all three cell types. n = 5 embryos (308 cells) for mid-blastocyst stage and three embryos (448 cells) for late blastocyst stage. See [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} for immunohistochemistry of additional stages. (**C**) Quantification of nuclear levels of Zfp281 in VE and Epi cells in WT and *Zfp281*KO embryos at E5.75 using Imaris software. n = 6 embryos for the WT (20 cells per genotype) and n = 3 embryos for *Zfp281*KO. The expression of Zfp281 in the VE was ruled out through quantitative fluorescence level comparisons of wild-type (WT) and *Zfp281*KO embryos, which lack Zfp281 protein. (**D**) At E6.5, the A-P axis is established and WT embryos initiate gastrulation at their posterior, while *Zfp281*KO embryos display a thickened visceral endoderm epithelium (black arrowhead) and no A-P polarity. Insets (top-right) depict thickened VE layer (delineated by black dashed lines) in *Zfp281*KO embryo compared to the WT. (**E**) *Zfp281*KO embryos die around E8.0 and exhibit aberrant gross morphology at E7.75 when compared to WT with either cells of the epiblast layer undergoing apoptosis and/or constriction at the embryonic/extra-embryonic junction (white arrowheads). A = Anterior, p=Posterior, Pr = proximal, D = Distal, BF = brightfield, Scale bars represent 50 µm. Statistical significance was calculated on the average level of corrected fluorescence per embryo using Student T-test.](elife-33333-fig1){#fig1}

Despite its critical function in maintaining ESC pluripotency ([@bib66]; [@bib30]) and promoting the transition from the naive-to-primed state of pluripotency in vitro ([@bib29]), whether Zfp281 plays a role within the epiblast lineage of the developing embryo remained an open question. A conventional knockout (KO) allele of Zfp281 generated using a gene targeting approach ([@bib30]) was used for embryo analysis. No homozygous mutant mice were recovered at birth from intercrosses of heterozygous animals, demonstrating a requirement for Zfp281 in embryonic development ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). The analysis of staged embryos revealed that mutants died around E8.0 ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). At E5.5, *Zfp281*KO embryos were recovered at Mendelian ratios and were indistinguishable from their WT and heterozygous littermates by gross morphology ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). However, by E6.0--6.5, *Zfp281* mutants became readily distinguishable from their WT littermates by their smaller size and distinct morphology, exhibiting a thickened VE layer ([Figure 1D](#fig1){ref-type="fig"}, insets, [Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}, insets with yellow bars). These results suggest a requirement of Zfp281 for both the VE and epiblast, which are likely to be non-cell-autonomous and cell-autonomous, respectively, given the epiblast-specific expression of Zfp281.

To confirm the epiblast-specific function of Zfp281, we produced embryos in which Zfp281 was specifically absent in the epiblast, but in which TE and PrE derivatives were wild-type (WT). To do this we generated tetraploid (4n) WT \<-\>*Zfp281*KO ESC chimeras and analyzed them at early post-implantation stages ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}). Epiblast-specific loss of Zfp281 produced embryos with a comparable phenotype to that of constitutive gene ablation, with both types of mutant embryos exhibiting a thickened VE ([Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"}). The defect observed in tetraploid chimeras comprising *Zfp281*KO ESCs could be partially rescued when a Zfp281 cDNA was transfected into *Zfp281*KO ESCs (referred to as *Zfp281*KO + Zfp281 cDNA), further confirming the epiblast tissue specificity and Zfp281 gene specificity in the observed mutant phenotypes.

By E7.75, mutant embryos appeared grossly abnormal and displayed either a constriction at the embryonic and extra-embryonic boundary ([Figure 1E](#fig1){ref-type="fig"}, white arrowheads), resembling the DVE/AVE defects observed in mutant embryos lacking Eomes ([@bib46]), Otx2 ([@bib1]), Lim1/Lhx1 ([@bib54]; [@bib19]), Cripto ([@bib23]), Foxh1 ([@bib69]), and Foxa2 ([@bib2]), or they exhibited extensive cell death and a massive loss of epiblast cells ([Figure 1E](#fig1){ref-type="fig"}). Together, these results suggest a cell-autonomous requirement for Zfp281 within the epiblast, and a non-cell-autonomous requirement within the VE.

Deregulation of Nodal signaling and A-P axis specification related genes in *Zfp281*KO embryos {#s2-2}
----------------------------------------------------------------------------------------------

To identify the molecular changes associated with loss of Zfp281, we characterized the transcriptomic differences between WT and *Zfp281*KO embryos. We performed RNA sequencing (RNA-seq) on individual E6.5 embryos, corresponding to the earliest stage at which mutants could be morphologically distinguished from WT littermates ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We identified 968 and 792 transcripts that were significantly downregulated and upregulated, respectively, in *Zfp281*KO versus WT embryos ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Among the significantly downregulated genes were components of the Nodal signaling pathway (e.g., *Nodal*, *Foxh1*, *Cripto*, *Lefty1*, *Lefty2*), and genes regionally-restricted in the epiblast and its derivatives (e.g., *Fgf5, Otx2, Gsc*) or the VE (e.g., *Cer1*, *Lhx1, Dkk1, Hex, Hesx1*) ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). We also identified a number of genes that were significantly upregulated in mutant embryos, including *Afp*, *Patched1 (Ptch1), Gsn* ([Figure 2A](#fig2){ref-type="fig"}). Gene ontology (GO) analysis for the downregulated genes revealed the top enriched biological process to be A-P axis specification ([Figure 2B](#fig2){ref-type="fig"}). Gene set enrichment analysis (GSEA) revealed that Nodal was the top-ranking signaling pathway enriched in the downregulated genes ([Figure 2C](#fig2){ref-type="fig"}). Of note, this gene set is also included in the GO term A-P axis specification. We next performed RT-qPCR analysis on E6.5 embryos, and confirmed differential expression of genes that are components of the Nodal signaling pathway, Anterior/AVE markers, and posterior/lineage markers, as well as a few genes that were upregulated in *Zfp281*KO embryos compared to WT embryos ([Figure 2D](#fig2){ref-type="fig"}), consistent with our transcriptome data ([Figure 2A](#fig2){ref-type="fig"}). Together, these data demonstrate that Nodal signaling and A-P axis specification, two key events associated with epiblast maturation, were perturbed in the absence of Zfp281.

![*Zfp281*KO embryos exhibit defects in Nodal signaling and expression of genes associated with anterior-posterior patterning.\
(**A**) Heatmap of genes differentially regulated between WT and *Zfp281*KO embryos (E6.5). (**B**) Gene ontology (GO) analysis for significant downregulated genes (fold-change \<4, p-value\<0.05) in *Zfp281*KO embryos. (**C**) Gene set enrichment analysis (GSEA) shows Nodal signaling as top pathway in downregulated genes in *Zfp281*KO embryos. (**D**) RT-qPCR for expression of genes at E6.5. For each genotype, n = 6 embryos. mRNA levels of WT embryos were normalized to 1. Student T-test was used examine statistical significance: ns = non significant, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. RT-qPCR primer sequences are provided in [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.33333.009Figure 2---source data 1.RPKM values of significantly up- and down-regulated genes in WT and *Zpf281*KO embryos RNA-seq data.\
10.7554/eLife.33333.010Figure 2---source data 2.RT-qPCR primer sequences.](elife-33333-fig2){#fig2}

Zfp281 controls hallmark molecular events in the exit from naive pluripotency {#s2-3}
-----------------------------------------------------------------------------

Changes in the expression of some of the stage-specific pluripotency-associated genes ([Figure 2](#fig2){ref-type="fig"}) prompted us to investigate this hallmark molecular event involved in the naive-to-primed transition. Under normal development, the pluripotency factors Sox2 and Oct4 are similarly expressed throughout the naive-to-primed transition. On the other hand, Nanog is rapidly shut down after E4.5 ([@bib15]) and expressed again from E6.0 onwards in the epiblast ([@bib32]). Nanog is also downregulated in EpiSCs ([@bib56]). Consistent with our RNA-seq data, we noted that Sox2 and Nanog protein levels were unaffected in *Zfp281*KO embryos ([Figure 3A,D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) or in tetraploid chimeras ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). In contrast, Oct4 protein was significantly downregulated in E6.25 *Zfp281*KO embryos ([Figure 3B,D](#fig3){ref-type="fig"}). Additionally, Otx2, which is activated during the naive-to-primed transition and critical for activation of epiblast gene-related enhancers ([@bib14]), was expressed at significantly reduced levels ([Figure 3C,D](#fig3){ref-type="fig"}) and mislocalized at the distal tip of mutant embryos, rather than being anteriorly restricted as in WT ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). This downregulation of Otx2 protein expression was already visible at an earlier stage in *Zfp281*KO embryos and in tetraploid chimeras, together with the downregulation of another marker of primed pluripotency, Oct6 ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}), further indicating that epiblast maturation is defective in *Zfp281*KO embryos.

![Zfp281 regulates pluripotency-associated factors and Otx2.\
(**A**) Immunostaining of Nanog and Sox2 in WT and *Zfp281*KO embryos (E6.25). (**B**) Immunostaining of Oct4 in WT and *Zfp281*KO embryos (E6.25). (**C**) Immunostaining of Otx2 in WT and *Zfp281*KO embryos (E6.75). (**D**) Fluorescent intensity quantification of Nanog, Sox2, Oct4 and Otx2 proteins (each dot representing the mean corrected fluorescence level per epiblast cell) using Imaris software. For each genotype, n = 3 embryos (30 cells quantified per embryo). Statistical significance was calculated on the average level of corrected fluorescence per embryo using Student T-test. (**E**) Immunohistochemistry of pluripotency factor Nanog which is localized to posterior epiblast in WT embryos, and the primitive streak marker T, exhibit radialized expression in mutant compared to WT (E7.0). Additionally, in *Zfp281*KO, the mutually-exclusive pattern of Nanog and T observed in WT is lost and proteins colocalize in a subset of cells. High magnification insets (top-left) show distribution in regions highlighted. (**F**) WISH of E6.75 *Zfp281*KO and WT littermate embryos. Markers of the primitive streak T and Fgf8 are radialized in *Zfp281*KO embryos compared to WT. A = Anterior, p=Posterior, Pr = proximal, D = Distal, Scale bars represent 50 µm.](elife-33333-fig3){#fig3}

Another hallmark of the naive-to-primed transition is the expression of lineage-specific genes at the posterior part of the embryo, marking the site of the primitive streak and onset of gastrulation. We noted that the T protein is expressed in *Zfp281*KO embryos ([Figure 3E](#fig3){ref-type="fig"}). However, cells that started expressing T, had not downregulated Nanog (see inset in [Figure 3E](#fig3){ref-type="fig"}), indicating a failure in the extinguishment of pluripotency-associated genes as epiblast cells committed to differentiate in *Zfp281*KO embryos. The domains of both T and Nanog expression in mutant embryos were also proximally radialized, instead of being posteriorly restricted as in WT embryos ([Figure 3E](#fig3){ref-type="fig"}). This radialization of normally posteriorly-localized markers was also observed in tetraploid *Zfp281*KO ESCs chimeras ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). Notably, this phenotype was rescued in tetraploid WT \<-\>*Zfp281*KO + Zfp281 cDNA ESC chimeras ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). Analysis of RNA expression by wholemount mRNA in situ hybridization (WISH) of other markers of the primitive streak such as *Fgf8, Axin2* and *Eomes* showed that, similarly to T, they were expressed and proximally radialized in mutant embryos ([Figure 3F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3B,C](#fig3s3){ref-type="fig"}). Our WISH and RNA-seq data both also revealed that levels of *Fgf8* were reduced upon Zfp281 loss. However, T, Axin2 and Eomes RNA levels were not significantly reduced in *Zfp281*KO embryos ([Figure 2D](#fig2){ref-type="fig"}). Therefore, Zfp281 is required for induction and proper localization of lineage specification markers.

Together, our data establish a requirement for Zfp281 in controlling key molecular events involved in the naive-to-primed transition in embryos, including extinguishment of pluripotency-associated and induction (or localization) of lineage specification transcriptional programs during epiblast maturation.

Zfp281 plays a critical role in Nodal signaling activation to promote DVE/AVE migration {#s2-4}
---------------------------------------------------------------------------------------

Execution of the naive-to-primed transition in the epiblast of early post-implantation embryos culminates in A-P axis formation, determined via cross-talk between the epiblast and VE through Nodal and Wnt signals ([@bib37]). The radialized expression of Nanog and several lineage specification factors in *Zfp281*KO embryos ([Figure 3E--F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"} and [Figure 3---figure supplement 3A--B](#fig3s3){ref-type="fig"}), as well as deregulation of genes involved in A-P axis specification ([Figure 2](#fig2){ref-type="fig"}) prompted us to examine the expression and localization of AVE/DVE markers. WISH of *Hesx1, Dkk1, Cer1, Hex,* and *Lefty1* revealed their absence or significantly reduced expression in *Zfp281*KO embryos ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). WISH for *Dkk1* of *Zfp281*KO tetraploid chimera confirmed this phenotype and showed a partial rescue using *Zfp281*KO + Zfp281 cDNA ESCs ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). In the few cases where expression was detected (e.g., *Hesx1* in *Zfp281*KO or *Dkk1* in tetraploid mutant chimera), it was localized at the distal tip of embryos, but not anteriorly as in WT ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}), suggesting that the DVE/AVE population was not specified, or could not be maintained or migrate. To distinguish these possibilities, we employed a *Hex-GFP* reporter line ([@bib51]) to visualize the AVE in *Zfp281*KO embryos. In agreement with our WISH data, *Hex*-GFP expression was reduced and distally-localized, consistent with a failure in maintenance leading to impaired migration of the DVE/AVE population ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). By contrast, the expression of proteins labeling the entire VE, such as *Gata6*, *Lhx1* and *Eomes*, was unaffected in *Zfp281* mutants ([Figure 4---figure supplement 2C,D](#fig4s2){ref-type="fig"}).

![Loss of Zfp281 affects pluripotent state progression and results in failure in anterior-posterior axis establishment.\
(**A**) WISH of E6.5 *Zfp281*KO and WT littermate embryos. Markers of DVE/AVE such as Hesx1, Dkk1, Cer1, Hex and Lefty1 are not expressed in *Zfp281*KO embryos compared to WT littermates, which exhibit distal-anterior domains of expression. Red arrowheads indicate the position of most anterior cells of the DVE/AVE. (**B**) Reduced expression and failure of anterior migration of Hex-GFP reporter in *Zfp281*KO embryos. Cell shape and organization within the VE layer is affected by absence of Zfp281 as indicated by distribution of F-Actin. White dashed line indicates the limit between extra-embryonic and embryonic regions. Quantification of nuclear levels of Hex-GFP at E5.75 (n = 2 embryos, 89 cells for WT and n = 3 embryos, 78 cells for *Zfp281*KO) and at E6.5 (n = 2 embryos, 193 cells for WT and n = 2 embryos, 89 cells for *Zfp281*KO) using Imaris software. Statistical significance was calculated on the average level of corrected fluorescence per embryo using Student's T-test. \*p\<0.05. (**C**) WISH analysis of the Nodal target Lefty2 shows loss of expression in *Zfp281*KO embryos. Nodal is radialized in *Zfp281*KO embryos compared to WT due to lack of A-P axis. A = Anterior, p=Posterior, Pr = Proximal, D = Distal, 2D = single optical section, 3D = projection of several optical section. Scale bars represent 50 µm.](elife-33333-fig4){#fig4}

Nodal and Wnt signaling pathways play a key role in DVE/AVE specification and migration ([@bib37]), and rank as top enriched GO terms in the downregulated genes from our RNA-seq data ([Figure 2C](#fig2){ref-type="fig"}). We already showed that levels of *Axin2* and *T*, two Wnt signaling targets, were unaffected by loss of Zfp281, although their expression was radialized due to failure in A-P axis specification ([Figures 2D](#fig2){ref-type="fig"} and [3F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). By contrast, the Nodal target and negative regulator *Lefty2* (expressed in the posterior epiblast of WT embryos) were absent in the epiblast of *Zfp281*KO embryos ([Figure 4C](#fig4){ref-type="fig"}), similarly to the related *Lefty1* gene, which is expressed earlier in the VE, and also absent in mutants *([Figure 4A](#fig4){ref-type="fig"}).* Nodal and Eomes are usually posteriorly localized in the epiblast at the site of the primitive streak ([@bib46]). However, their expression was radialized in *Zfp281*KO embryos ([Figure 4C](#fig4){ref-type="fig"} and [Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}) while Nodal expression levels were reduced ([Figure 2D](#fig2){ref-type="fig"} and [Figure 4---figure supplement 2E](#fig4s2){ref-type="fig"}).

Together, our data suggest an impairment of Nodal signaling in *Zfp281*KO embryos, leading to defects in DVE/AVE specification and migration, further corroborating a critical role for Zfp281 in promoting epiblast maturation.

Zfp281 regulates lineage-specific genes for transcriptional activation during epiblast maturation {#s2-5}
-------------------------------------------------------------------------------------------------

To understand the molecular mechanisms by which Zfp281 promotes epiblast maturation, we turned to the in vitro naive-to-primed transition model to identify Zfp281-regulated genes. We first examined expression of Zfp281-regulated genes in WT and *Zfp281*KO ESCs and epiblast-like cells (EpiLCs), which is an alternative of primed cells because *Zfp281*KO is detrimental to the self-renewal of EpiSCs ([@bib64]; [@bib29]). EpiLCs are derived by short-time (48 hr) adaption of ESCs to the primed cell culture condition, representing an intermediate state, known as the formative state ([@bib36]; [@bib57]), in the naive-to-primed transition ([@bib33]; [@bib14]). As expected, EpiLCs (WT) expressed higher levels of lineage-specific genes than ESCs ([Figure 5A](#fig5){ref-type="fig"}). However, levels of expression of these genes were reduced or abrogated in *Zfp281*KO relative to WT EpiLCs ([Figure 5A](#fig5){ref-type="fig"}), indicating Zfp281 is important for establishing or maintaining expression of these genes during the transition. In addition, while genes involved in Nodal signaling were similarly expressed in both WT ESCs and EpiLCs, their levels of expression were downregulated in *Zfp281*KO versus WT EpiLCs ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), consistent with their downregulation in *Zfp281*KO versus WT embryos ([Figure 2A,D](#fig2){ref-type="fig"}).

![Zfp281 activates lineage-specific genes during epiblast maturation.\
(**A**) Expressions of lineage-specific genes in WT and *Zfp281*KO ESCs and EpiLCs, from a previous published RNA-seq dataset ([@bib29]). mRNA expression level is mapped reads per million total mapped reads per kilobase (RPKM). (**B**) Zfp281 and H3K27me3 ChIP-seq tracks at loci of *T, Otx2, Eomes,* and *Gsc.* Black bar under track indicates region called as Zfp281 peak by MACS software. (**C**) ChIP-qPCR of Zfp281 at promoters (Pro) of *T, Otx2, Eomes,* and *Gsc* in ESCs and EpiSCs. Promoter and negative regions for PCR at each gene are shown in panel B. (**D**) ChIP-qPCR of H3K27me3 at promoters of *T, Otx2, Eomes,* and *Gsc. mCh6* is a negative control mapping to a gene desert region on chromosome 6 ([@bib11]). (**E**) Zfp281 and H3K27ac ChIP-seq tracks at loci of *Fgf5* and *Fgf8.* Black bar under track indicates region called as Zfp281 peak by MACS software. (**F**) ChIP-qPCR of Zfp281 at regulatory regions of *Fgf5* and *Fgf8* in ESCs and EpiSCs. Positions for PCR at each gene are shown in panel E. (**G**) ChIP-qPCR of H3K27me3 at regulatory regions of *Fgf5* and *Fgf8. mCh6* is a negative control mapping to a gene desert region on chromosome 6 ([@bib11]). ChIP-qPCR primer sequences are provided in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.33333.021Figure 5---source data 1.ChIP-qPCR primer sequences.](elife-33333-fig5){#fig5}

To investigate how Zfp281 exerts transcriptional control of downstream target genes, we performed chromatin immunoprecipitation (ChIP) with massively parallel sequencing (ChIP-seq) in both WT ESCs and EpiSCs, which revealed enrichment of Zfp281 binding at regions near gene transcription start sites (TSSs) and enhancers ([Figure 5---figure supplement 2A,B](#fig5s2){ref-type="fig"}), suggesting that Zfp281 is actively involved in transcriptional regulation in both naive and primed pluripotent states. There were 9358 common peaks for Zfp281, and 11,408 and 3467 peaks specific to ESCs and EpiSCs, respectively, which were lost and gained during the transition between these two states ([Figure 5---figure supplement 2C,D](#fig5s2){ref-type="fig"}), suggesting Zfp281 targets may be dynamically regulated during pluripotent state transition.

Next, we determined whether Zfp281 coordinately controls transcriptional programs associated with pluripotent state transition and lineage commitment through binding of regulatory regions of its target genes. Surprisingly, promoters (Pro) of lineage-specific genes such as *T, Otx2, Eomes, Gsc* were bound by Zfp281 with a higher enrichment in ESCs than in EpiSCs ([Figure 5B](#fig5){ref-type="fig"}). ChIP-qPCR analyses confirmed that Zfp281 binding intensities were reduced at these promoters in EpiSCs ([Figure 5C](#fig5){ref-type="fig"}). Consistent with the fact that these lineage-specific genes will be activated in primed cells, we also observed diminished intensities of repressive histone mark H3K27me3 on their promoters ([Figure 5D](#fig5){ref-type="fig"}). By contrast, there was no Zfp281 peak at promoters of *Fgf5* or *Fgf8*, indicating a promoter-independent regulation of Zfp281 on these two genes ([Figure 5E](#fig5){ref-type="fig"}). However, Zfp281 bound at promoter-distal regions of *Fgf5* and *Fgf8* ([Figure 5E--F](#fig5){ref-type="fig"}) accompanied with increased H3K27ac ([Figure 5G](#fig5){ref-type="fig"}) in EpiSCs, suggesting Zfp281 may be involved in enhancer activation on these two targets during the naive-to-primed transition. Indeed, a previous study has shown that the two Zfp281 peaks (P1, P2) comprising enhancers of *Fgf5* are critical for the naive-to-primed transition ([@bib14]). Taken together, our data indicate that Zfp281 regulates lineage-specific genes during epiblast maturation through both promoter- and enhancer-related mechanisms.

Zfp281 is associated with chromatin modifiers for promoter activation of lineage-specific genes {#s2-6}
-----------------------------------------------------------------------------------------------

To further understand how Zfp281 controls transcription of target genes in relation to their promoter chromatin architecture, we investigated the genome-wide association of Zfp281 with other epigenetic regulators and TFs in ESCs. Hierarchical clustering analysis for ChIP-seq association revealed that Zfp281 and Ep400 have the most similar binding patterns. Furthermore, Zfp281 and Ep400 also show similar binding patterns with the Polycomb repressive complex 2 (PRC2) components Ezh2 and Suz12 ([Figure 6A](#fig6){ref-type="fig"}). Ep400 is a component of the Tip60-Ep400 histone acetyltransferase complex that is necessary to maintain ESC self-renewal ([@bib27]; [@bib16]). A previous study showed that Ep400 localization to promoters depends on H3K4me3, and Ep400 promotes histone H4 acetylation at both active and silent target promoters in ESCs ([@bib27]). We profiled ChIP-seq intensities of Ep400, Suz12 (a component of PRC2 that modifies H3K27me3), Mbd3 and histone marks H3K4me3, H3K27ac, and H3K27me3 at Zfp281 peak regions ([Figure 6B](#fig6){ref-type="fig"}). Mbd3 is a core component of NuRD histone deacetylation complex that can be recruited by Zfp281 for repression of pluripotency genes ([@bib28]). Zfp281 and Ep400 peaks exhibited a high correlation across the genome, but were mutually exclusive with Suz12 and Mbd3 peaks, dividing Zfp281 peaks into two classes: (I) Zfp281/Ep400/Suz12-cobound, and (II) Zfp281/Ep400/Mbd3-cobound ([Figure 6B](#fig6){ref-type="fig"}). Class I and Class II characterize the epigenetic features of target genes in ESCs, and are highly enriched for GO terms that signify development and pluripotency, respectively ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). The Class I genes are bivalent with a feature of H3K4me3 and H3K27me3 co-enrichment ([Figure 6B](#fig6){ref-type="fig"}). Bivalent genes remain silent in ESCs while undergoing fast activation in response to differentiation signals ([@bib8]). Our study demonstrates that Zfp281 regulates active and bivalent genes by associating with identical (Ep400 for both Class I and Class II) or distinct (PRC2 for Class I versus NuRD for Class II) epigenetic regulators.

![Zfp281 associates with PRC2 and Ep400 complexes for promoter regulation of bivalent lineage genes.\
(**A**) Heatmap of ChIP-seq association analysis of Zfp281 with other transcription factors and epigenetic regulators in ESCs. The ChIP-seq datasets were compiled from published studies (see [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"} for the accessions). The scale represents Phi correlation coefficient. (**B**) ChIP-seq profiles of Zfp281, Ep400, Suz12, Mbd3, and histone marks H3K4me3, H3K27me3, and H3K27ac at Zfp281 peak regions. Intensity is plotted within 5 kb around Zfp281 peak center. Two classes of Zfp281 peaks are shown: Class I, Zfp281-Mll2-Ep400-Suz12 co-bound; Class II, Zfp281-Mll2-Ep400-Mbd3 co-bound. (**C**) Co-immunoprecipitation (co-IP) of Zfp281 with other epigenetic regulators in ESCs and EpiSCs. (**D**) ChIP-seq tracks of Zfp281 and PRC2 complex (Suz12) at bivalent *T* and *Eomes* promoters. (**E**) ChIP-qPCR shows Suz12 binding at *T* and *Eomes* promoters decreases in *Zfp281*KO ESCs.\
10.7554/eLife.33333.024Figure 6---source data 1.Accession numbers of ChIP-seq data used in [Figure 6A](#fig6){ref-type="fig"}.](elife-33333-fig6){#fig6}

We next asked whether Zfp281 associates with these epigenetic modifiers during the naive-to-primed transition. While we confirmed interactions of the PRC2 (Suz12) and NuRD (Chd4, Mbd3) complexes with Zfp281 in ESCs, we found their associations with Zfp281 were reduced in EpiSCs despite their expression levels being similar in the two populations ([Figure 6C](#fig6){ref-type="fig"}). By contrast, Zfp281\'s interaction with components of the Tip60-Ep400 complex (Ep400, Trrap) was maintained in both ESCs and EpiSCs ([Figure 6C](#fig6){ref-type="fig"}). Loss of interaction between Zfp281 and the PRC2 complex may be responsible for the activation of Zfp281 target genes during the transition, providing a parsimonious explanation for the upregulation of lineage specification genes ([Figure 5B--C](#fig5){ref-type="fig"}) and reduction of H3K27me3 ([Figure 5D](#fig5){ref-type="fig"}) in EpiSCs versus ESCs. The lack of association between Zfp281 and NuRD in EpiSCs may also explain why pluripotency genes including *Sox2* and *Nanog* are not regulated by Zfp281 in the epiblast ([Figure 3A,D](#fig3){ref-type="fig"}), which is in contrast with NuRD-mediated Nanog repression in ESCs due to their physical association ([@bib28]). We confirmed the reduced chromatin occupancy of Suz12 at bivalent promoters of *T* and *Eomes* in *Zfp281*KO relative to WT ESCs ([Figure 6D--E](#fig6){ref-type="fig"}), indicating a Zfp281-dependent recruitment of PRC2 at the bivalent promoters. However, we cannot exclude the possibility that the residual binding of Zfp281 to bivalent promoters (e.g., *T* and *Eomes* in [Figure 5C](#fig5){ref-type="fig"}) with maintained Tip60-Ep400 complex association during the naive-to-primed transition may further reinforce the activation of lineage-specific genes through the presumed role of Tip60-Ep400 in outcompeting PRC2, and thus downregulating the promoter H3K27me3 levels ([@bib16]).

Taken together, our data reveal an important role of Zfp281 in regulating bivalent promoters during the naive-to-primed pluripotency transition. Reduced association between Zfp281 and the PRC2 complex, but preservation of the Zfp281-Ep400 association, at bivalent promoters results in decreased H3K27me3 during this transition, leading to transcriptional activation of lineage-specific genes concomitant with epiblast maturation.

Zfp281 cooperates with Oct4 and P300 for regulation of Nodal signaling components in epiblast maturation {#s2-7}
--------------------------------------------------------------------------------------------------------

We have shown that Zfp281 is necessary for activation of Nodal signaling components in the embryo ([Figure 2](#fig2){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}). Next, we investigated activity of Nodal signaling by examining Smad2 phosphorylation (p-Smad2) in WT and *Zfp281*KO ESCs. P-Smad2 is significantly reduced in *Zfp281*KO ESCs compared to that in WT ESCs ([Figure 7A](#fig7){ref-type="fig"}). Since *Zfp281*KO EpiSCs cannot be maintained in long-term culture ([@bib29]), we performed shRNA-mediated knockdown (KD) of Zfp281 in EpiSCs. P-Smad2 is not affected by *Zfp281*KD in EpiSCs, probably because of the Activin in culture constitutively activating p-Smad2. However, protein expression of the Nodal signaling target Lefty significantly decreased by *Zfp281*KD ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}), suggesting that Zfp281 may directly regulate Lefty expression. Similarly, reduction of Lefty protein expression is reproduced by treatment of ALK receptor inhibitor (ALKi) that specifically blocks p-Smad2 and Nodal signaling ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). In addition, as activation of WNT and Nodal signaling pathways can differentiate ESCs to primitive-streak (PS)-like cells ([@bib44]), we also investigated the role of Zfp281 in this differentiation. ESCs were treated with Activin (a Nodal ligand) and CHIR (a GSK3β inhibitor to activate WNT pathway), and with ALKi or Zfp281 shRNAs. The morphology of *Zfp281*KD cells revealed a strong phenotype of differentiation resistance, which is similar to that of ALKi treatment. Dome-shaped ESC-like colonies persisted in *Zfp281*KD cell cultures after Activin/CHIR treatment, a striking difference compared to WT control cells ([Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}). RT-qPCR for up to 3 days after treatment indicated both *Zfp281*KD- and ALKi-treated cells exhibited decreased expression of the PS marker genes *T* and *Lefty2* (a Nodal signaling target gene also expressed in PS) ([Figure 7---figure supplement 2B,C](#fig7s2){ref-type="fig"}).

![Zfp281 cooperates with Oct4 and P300 for regulation of genes encoding Nodal pathway components.\
(**A**) Protein expression of p-Smad2 and Smad2 in WT (J1, CJ7, WT clone no 3), *Zfp281*KO (clone no. 2.6, 7, 3.34) ESC and WT EpiSC (OEC2, EpiSC9) cells. P-Smad2/Smad2 density ratios were quantified on the right panel. Student T-test was used examine statistical significance, \*p\<0.05. (**B**) Co-IP of Zfp281 with Oct4 and P300 in EpiSCs. The non-specific band is IgG heavy chain. (**C**) ChIP-seq tracks of Zfp281, Oct4 and P300 in ESCs and EpiSCs/EpiLCs at *Nodal*, *Lefty2*, and *Foxh1* loci. Intensities are shown as mapped reads per million total mapped (RPM). (**D**) ChIP-qPCR of Zfp281 at *Nodal*, *Lefty2, and Foxh1* regulatory regions in in ESCs and EpiSCs. (**E**) ChIP-qPCR of histone markers H3K27me at *Nodal*, *Lefty2, and Foxh1* regulatory regions in ESCs and EpiSCs. (**F**) Diagram of ChIP experiments on E6.5 (WT) embryos. (**G**) ChIP-qPCR of Zfp281 at *Nodal*, *Lefty2, and Foxh1* regulatory regions in E6.5 (WT) embryos. ChIP experiments were performed in two independent replicates. ChIP-qPCR primer sequences are provided in [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.33333.029Figure 7---source data 1.ChIP-qPCR primer sequences.](elife-33333-fig7){#fig7}

To understand the molecular regulation of the Nodal signaling pathway by Zfp281, we employed ChIP-seq analysis and revealed that Zfp281 localizes to distal regions of *Nodal* and *Lefty2*, as well as promoters of *Foxh1* ([Figure 7C](#fig7){ref-type="fig"}). Previous studies indicated that transcription factors Oct4, Otx2, and histone acetyltransferase P300 (the writer of H3K27ac) associate with enhancer reorganization in the naive-to-primed transition ([@bib14]; [@bib70]). We first confirmed that Zfp281 interacts with Oct4 and P300 in EpiSCs ([Figure 7B](#fig7){ref-type="fig"}). However, we did not detect the Zfp281-Otx2 interaction in EpiSCs (data not shown). Furthermore, ChIP-seq analysis indicates that Zfp281 co-localizes with Oct4 and P300 ([@bib14]) in almost all Zfp281 peaks ([Figure 7C](#fig7){ref-type="fig"}, [Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}), suggesting that Zfp281 may be involved in widespread relocation of Oct4 and P300, including both promoters and enhancers, in the naive-to-primed transition, that is independent of Otx2 association.

Zfp281 localizes to characterized enhancers within the *Nodal* locus (PEE, NDE, HBE, but not ASE, nomenclature from \[[@bib49]\]) ([Figure 7C](#fig7){ref-type="fig"}). ChIP-qPCR analysis confirmed that Zfp281 intensities are comparable between PEE and NDE, but decreased at HBE in EpiSCs compared to ESCs ([Figure 7D](#fig7){ref-type="fig"}). Zfp281 intensity by ChIP-qPCR was relatively low at ASE, consistent with our ChIP-seq data ([Figure 7C--D](#fig7){ref-type="fig"}). It is reported that, during the naive-to-primed transition, *Nodal* enhancer activity relocates from the HBE to the ASE ([@bib49]). Indeed, H3K27ac intensity was also reduced at HBE ([Figure 7E](#fig7){ref-type="fig"}), consistent with reduced Zfp281 binding at this locus during the naive-to-primed transition ([Figure 7D](#fig7){ref-type="fig"}). We also evaluated Zfp281 intensities by ChIP-qPCR at an enhancer of *Lefty2* and the promoter of *Foxh1*, and found high intensities of Zfp281 and H3K27ac, colocalizing with P300 and Oct4 peaks at these loci in ESCs and EpiSCs ([Figure 7C--E](#fig7){ref-type="fig"}). Zfp281 binding at regulatory regions of these Nodal signaling-related genes is biologically important, as expression of Lefty2 is downregulated by *Zfp281*KD in EpiSCs ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}), and many of Nodal signaling genes were perturbed in *Zfp281*KO EpiLCs relative to their WT counterparts ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), supporting a critical role of Zfp281 in transcriptional activation of Nodal signaling during the transition to primed pluripotency in vitro. To provide direct evidence that Zfp281 binds and regulates these Nodal signaling related genes in vivo, we performed ChIP experiments on E6.5 WT embryos ([Figure 7F](#fig7){ref-type="fig"}). Zfp281 exhibited high chromatin-binding activity at the HBE enhancer of the *Nodal* locus, as well as the regulatory regions within the *Lefty2* and *Foxh1* loci ([Figure 7G](#fig7){ref-type="fig"}), which would be abrogated in *Zfp281* mutant embryos. Together, our data demonstrate that Zfp281, together with P300 and Oct4, are important for regulation of components of the Nodal signaling pathway during the maturation of the epiblast of the mouse embryo.

Discussion {#s3}
==========

Pluripotency is a continuum where the naive and primed states represent the initial and final stages, corresponding to the establishment of pluripotency in the pre-implantation blastocyst and the exit from pluripotency as cells of the post-implantation epiblast initiate gastrulation. While the in vitro pluripotent state transition model provides a useful tool to infer how the epiblast transitions between states and prepares for germ layer differentiation ([@bib67]), it cannot substitute for direct investigations into the transition occurring during epiblast maturation in vivo in embryos. Notably, none of the pluripotency-associated factors, for which mouse mutants are available, have described phenotypes directly associated with the exit from naive pluripotency in the embryo. Zfp281 is the first factor demonstrated to be critical in vivo for this developmental transition; its loss results in embryonic lethality due to a failure in epiblast maturation. Our data reveal that Zfp281 is concomitantly required for the initiation of expression of genes encoding Nodal signaling components and the lineage specification program during epiblast maturation. Zfp281 coordinates crosstalk among multiple epigenetic pathways through physical association with histone methylation (PRC2) and acetylation (Ep400, P300) complexes within epiblast cells. Crosstalk converges on the coordinated regulation of bivalent promoters and reorganization of enhancers leading to activation of lineage-specific genes and downregulation of pluripotency genes during the naive-to-primed transition, arguing for a master regulator status of Zfp281 in controlling key molecular events leading to epiblast maturation ([Figure 8](#fig8){ref-type="fig"}, top panel). Accordingly, loss of Zfp281 results in a series of developmental defects within the epiblast, which non-cell-autonomously lead to a failure to establish or maintain the DVE/AVE resulting in A-P axis specification defects ([Figure 8](#fig8){ref-type="fig"}, bottom panel).

![Working model for the role of Zfp281 in epiblast maturation.\
Upper panel describes a working model for Zfp281 function during epiblast maturation in the post-implantation embryo. Zfp281 is expressed in epiblast cells (blue) and directs the activation of target genes. The lower panel describes the *Zfp281*KO embryo phenotype. Defects in epiblast maturation and Nodal signaling lead to failure in anterior-posterior axis establishment. Markers of the posterior epiblast (red) are radialized.](elife-33333-fig8){#fig8}

The in vitro pluripotent stem cell models overcome the limitation of embryo material and so have been instrumental in dissecting molecular events involved in the naive-to-primed transition ([@bib14]; [@bib26]) as well as the regulation of the Nodal signaling pathway during epiblast maturation ([@bib49]; [@bib50]). Our combined in vitro and in vivo studies have demonstrated high consistency of the regulatory functions of Zfp281 on the lineage-specific genes ([Figure 2](#fig2){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"}). However, there are also some differences between our findings in embryos and those made in pluripotent stem cell models. For instance, embryo RNA-seq data indicated non-significant changes in expression of lineage markers T and Eomes between WT and *Zfp281*KO embryos ([Figure 2D](#fig2){ref-type="fig"}), while their expression was markedly downregulated in *Zfp281*KO EpiLCs ([Figure 5A](#fig5){ref-type="fig"}). This disparity could be due to EpiLC representing a pluripotent state that does not match with the embryonic stage examined for RNA-seq in embryos, and/or extra-embryonic expression, in the case of Eomes in vivo ([@bib46]) ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}), that is not represented in EpiLC culture. Similarly, *Zfp281*KO embryonic phenotypes described for the VE layer cannot be reproduced in vitro since there is no equivalent cell population in ESC/EpiSC cultures. We noted that the morphology of VE cells in *Zfp281*KO embryos was different from the WT and resembled their adjacent extra-embryonic VE cells ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). As we identified that *Afp*, a pan-VE marker whose downregulation is coincident with the onset of gastrulation ([@bib65]), is upregulated in our mutant embryos ([Figure 2A,D](#fig2){ref-type="fig"}), we speculate that *Zfp281*KO embryos may also fail in VE maturation.

Furthermore, we also observed that Nodal signaling was significantly reduced in *Zfp281*KO embryos ([Figure 2D](#fig2){ref-type="fig"}), whereas in EpiSCs, p-Smad2 level was not affected by *Zfp281*KD ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). We speculate that this discrepancy may be attributable to the presence of Activin in the primed cell culture medium, which constitutively activates Nodal signaling. Compared to the in vitro system, crosstalk between the in vivo epiblast and its adjacent extra-embryonic tissues is dynamic and context-dependent, and unable to be precisely captured in a single defined cell culture system. Moreover, mRNA and protein levels of Oct4 and Otx2, the two factors required for reorganization of the enhancer landscape during the naive-to-primed transition ([@bib14]), are significantly downregulated in *Zfp281*KO embryos ([Figure 2D](#fig2){ref-type="fig"} and [Figure 3B--D](#fig3){ref-type="fig"}), which may also explain why Nodal signaling fail to be activated in epiblast maturation ([Figure 7](#fig7){ref-type="fig"}). Taken together, our studies highlight the importance of direct in vivo functional investigations using mouse models to refine and/or authenticate in vitro findings of pluripotent state transitions for a better understanding of epiblast maturation.

Nodal signaling has been extensively studied in key sequential events ranging from epiblast maturation to left-right patterning ([@bib55]). In *Nodal* mutant embryos, epiblast cells do not mature properly and embryos exhibit a failure in DVE/AVE establishment ([@bib12]; [@bib43]). A recent study suggests that Nodal guides the transition from naive to formative pluripotency in vitro (Mulas et al., 2017). Although pluripotency factors have been reported to occupy and regulate enhancers at the *Nodal* locus during the ESC-to-EpiSC transition ([@bib49]), how they contribute to lineage specification during the exit from a naive pluripotent state in vivo has remained an open question. Our work reveals that Zfp281 acts as a master regulator of epiblast maturation through the regulation of primed pluripotency genes and Nodal signaling components. Zfp281 binds the PEE, NDE, and HBE *Nodal* enhancers in vitro and in vivo, with binding at the HBE decreasing during epiblast maturation. In ESCs, HBE is bound by Oct4/Sox2/Nanog/Klf4 ([@bib49]), as well as Zfp281, however neither Zfp281 nor Oct4 binds ASE ([Figure 7C](#fig7){ref-type="fig"}), suggesting that loss of Zfp281 binding at HBE may be a prerequisite for decommissioning the naive-specific *Nodal* enhancer in transitioning to the primed state. In addition, Nodal expression is reduced or not restricted proximally in *Zfp281*KO embryos, which could further indicate a failure in enhancer switching. Our findings are thus in agreement with the proposed switch of *Nodal* enhancers, from HBE to ASE, concomitant with the transition from ESCs to EpiSCs ([@bib49]). Together with the crosstalk between Zfp281 and mulitiple histone modifying complexes (PRC2/Ep400/NuRD) ([Figure 6](#fig6){ref-type="fig"}), our data have thus uncovered a critical role for the pluripotency factor Zfp281 in coordinating transcriptional and epigenetic control of the exit from naive pluripotency through promoter and enhancer remodeling, leading to activation of lineage-specific genes and genes encoding Nodal signaling components while embryos are progressing to a primed pluripotency state during epiblast maturation ([Figure 8](#fig8){ref-type="fig"}).

As the targets and antagonists of Nodal signaling in embryo development, *Lefty* genes (*Lefty1* and *Lefty2*) are sensitive to status of DNA methylation at promoters. It is reported that ESCs depleted of Tet1 diminished expression of Lefty1 with DNA hyper-methylation at *Lefty1* promoter ([@bib38]). Our previous work indicated that Zfp281 physically interacts with Tet1 ([@bib29]), therefore Zfp281 may recruit Tet1 at *Lefty1/2* promotors and maintain Lefty expression, suggesting a Nodal signaling-independent role of Zfp281. Although, developmental arrest of *Zfp281* mutant embryos (\~E6.5) precedes that of Tet-TKO (triple KO) mutants (\~E7.5), and defects observed in Tet-TKO mutants were attributed to downregulation of Lefty1/2 through promoter hyper-methylation, leading to constitutive activation of the Nodal signaling pathway due to the disruption of Lefty-mediated negative-feedback ([@bib21]). Therefore, these results raise the question of a possible link between Zfp281 and DNA modification for epigenetic control of proper embryonic development, which is worthy of future investigation.

Materials and methods {#s4}
=====================

Mouse strains, embryo collection and staining {#s4-1}
---------------------------------------------

Mouse strains used in the study were *Zfp281*KO ([@bib30]) and *Hex-GFP* ([@bib51]). All mice used in this study were maintained in accordance with the guidelines of the Memorial Sloan Kettering Cancer Center (MSKCC) Institutional Animal Care and Use Committee (IACUC) under protocol number 03-12-017 (PI Hadjantonakis).

Pre-implantation embryos were flushed in M2 medium and processed according to standard protocols ([@bib52]). Post-implantation embryos were dissected in DMEM/F12 medium supplemented with 5% newborn calf serum and fixed for 20 min in PBS-4% PFA at room temperature for immunohistochemistry or overnight (o/n) at 4°C for wholemount RNA in situ. Following washes in PBS, embryos were permeabilized in PBS-0.5% Triton for 20 min at room temperature, washed in PBS-0.1% Triton (PBT) and blocked at 4°C o/n in PBT-3% BSA. Primary and secondary antibody stainings were performed o/n at 4°C. Counterstaining with Hoechst and fluorophore-coupled phalloidin (Life Technologies, Carlsbad, CA) were performed for 1 hr at room temperature prior to imaging on a Zeiss LSM880 laser scanning confocal microscope. Details of antibodies used in this study can be found below. Fluorescence intensity levels were measured on data acquired with the same imaging parameters. Pre-implantation fluorescence was quantified with our semi-automated MINS 3D nuclear segmentation software ([@bib41]; [@bib52]). Post-implantation nuclear protein levels were quantified using Imaris software (Bitplane) by manually creating individual nuclear surfaces for each cell and quantifying the fluorescence level inside the volume defined by these surfaces. Fluorescence levels were corrected for fluorescence decay along the z axis. Statistical significance was calculated on the average level of corrected fluorescence per embryo using unpaired two-tailed Student T-test (with Welch\'s correction when standard deviations differed between samples). Each graph represents either corrected fluorescence values per cell or transformed values using natural log (to represent different protein levels on a similar scale). Primary antibodies used for embryo staining were: Zfp281 (Santa Cruz, sc-166933, 1:200, RRID:[AB_10612046](https://scicrunch.org/resolver/AB_10612046)), Nanog (Reprocell, RCAB002P-F, 1:500, RRID:[AB_2616320](https://scicrunch.org/resolver/AB_2616320)), Gata6 (R and D, AF1700, 1:100, RRID:[AB_2108901](https://scicrunch.org/resolver/AB_2108901)), Brachyury/T (R and D, AF2085, 1:100, RRID:[AB_2200235](https://scicrunch.org/resolver/AB_2200235)), Oct4 (Santa Cruz, sc-9081X, 1:1000, RRID:[AB_2167703](https://scicrunch.org/resolver/AB_2167703)), Sox2 (R and D, AF2018, 1:50, RRID:[AB_355110](https://scicrunch.org/resolver/AB_355110)), Lhx1 (R and D, MAB2725, 1:250, RRID:[AB_2135636](https://scicrunch.org/resolver/AB_2135636)), Eomes (Abcam, ab183991, 1:500), Otx2 (R and D, AF1979, 1:1000, RRID:[AB_2157172](https://scicrunch.org/resolver/AB_2157172)), Oct6 (sc-376143, 1:100, RRID:[AB_10989975](https://scicrunch.org/resolver/AB_10989975)).

Whole-mount in situ hybridization (WISH) {#s4-2}
----------------------------------------

*Wholemount mRNA in situ hybridizations* were performed according to standard protocols ([@bib6]). The list and citation for each antisense probe used can be found in the following references: *Hesx1* ([@bib62]), *Dkk1* ([@bib31]), *CerI* ([@bib7]), *Hex* ([@bib63]), *Lefty1* ([@bib48]), *Lefty2* ([@bib42]), *Nodal* ([@bib71]), *Otx2* ([@bib2]), *T* ([@bib68]), *Eomes* ([@bib17]), *Axin2* ([@bib35]), and *Fgf8* ([@bib20]).

ESCs and EpiSCs cell culture {#s4-3}
----------------------------

Mouse embryonic stem cells (mESCs) J1 (strain 129S4/SvJae, RRID:[CVCL_6412](https://scicrunch.org/resolver/CVCL_6412),) and CJ7 (strain 129S1/SvImJ, RRID:[CVCL_C316](https://scicrunch.org/resolver/CVCL_C316)) were cultured on 0.1% gelatin-coated plates in ESM medium: DMEM supplemented with 15% fetal bovine serum (FBS), 1000 units/mL recombinant leukemia inhibitory factor (LIF), 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 0.1 mM MEM non-essential amino acids (NEAA), 1% nucleoside mix (100X stock, Sigma), and 50 U/mL Penicillin/Streptomycin). Primed mouse epiblast stem cells (EpiSCs) were culture on fibronectin-coated plates (10 μg/mL/cm^2^) in N2B27 medium supplemented with Activin A (20 ng/mL) and Fgf2 (12 ng/mL) ([@bib29]). Generation of *Zfp281*KO ESCs (from CJ7 background, clone no. 2.6 (XX), 3.34 (XY) and 7 (XX)) has been previously described ([@bib30]). All cell lines are from authenticated sources and mycoplasma contamination test was performed routinely.

Tetraploid WT \<-\> ESCs chimera {#s4-4}
--------------------------------

Tetraploid chimeras were generated according to standard protocols ([@bib24]; [@bib25]). Briefly, females were superovulated by i.p. injection of pregnant mares\' serum and human chorionic gonadotropin (HCG), and were then mated with males. Fertilized zygotes were isolated from oviducts 24 hr later, cultured until they reached the 2-cell stage, at which point they were electrofused. Fused 1-cell embryos were carefully identified, cultured for another 2 days, and then injected with about fifteen ESCs. ESCs from two *Zfp281*KO clones 2.6 (XX) and 3.34 (XY), and a Zfp281 cDNA rescued 3.34 clone (XY) were used for tetraploid injection. About 40 \~ 60 injected blastocysts were collected for each ES clone, and transferred into 2 \~ 3 pseudo-pregnant foster females. All experiments involving 2C-embryo electrofusion and tetraploid injection were performed at the Rodent Genetic Engineering Laboratory at New York University, with dissections of resulting post-implantation embryo chimeras taking place at MSKCC.

Knockdown of Zfp281, ALK inhibitor (ALKi) treatment and western blot analysis {#s4-5}
-----------------------------------------------------------------------------

Two shRNAs for Zfp281 knockdown were previously validated in our study ([@bib29]). Lentivirus production and infection were performed as described ([@bib34]). Concentrated viral supernatants were incubated with ESCs or EpiSCs for 1 hr, then cells were diluted with fresh medium. Blasticidin (10 µg/mL) was used for selection 24 hr later, and cells were harvested 72 hr after viral infection.

For ALKi treatment, ESCs and EpiSCs were treated with ALK inhibitor A83-01 (1 µM, \#2939, Tocris Bioscience) for 48 hr with DMSO as a vehicle control. Western blot analysis was carried out using the following primary antibodies: Zfp281 (sc-166933, Santa Cruz, RRID:[AB_10612046](https://scicrunch.org/resolver/AB_10612046)), p-Smad2 (\#3108, Cell Signaling, RRID:[AB_490941](https://scicrunch.org/resolver/AB_490941)), Smad2 (\#3103, Cell Signaling, RRID:[AB_490816](https://scicrunch.org/resolver/AB_490816)), Lefty (sc-365845, Santa Cruz, RRID:[AB_10847353](https://scicrunch.org/resolver/AB_10847353), detecting both Lefty1 and Lefty2), Gapdh (10494--1-AP, ProteinTech, RRID:[AB_2263076](https://scicrunch.org/resolver/AB_2263076)). Blot intensities were quantified using ImageJ software and Student T-test was used to examine statistical significance.

Induction of primitive streak (PS)-like cells {#s4-6}
---------------------------------------------

ESCs were seeded on fibronectin-coated plates, and treated with Activin A (20 ng/mL) and CHIR99021 (3 µM) for up to 3 days for PS-like cells inductions. Cells were also treated with ALK inhibitor (1 µM) or Zfp281 shRNAs to investigate the effects of Nodal signaling inhibition or Zfp281 knockdown during this differentiation. RNA was collected at different days after treatment.

Co-immunoprecipitation (coIP) {#s4-7}
-----------------------------

Two 15 cm dishes containing comparable numbers of confluent ESCs and EpiSCs were harvested, and nuclear extracts were prepared as described previously ([@bib18]). For immunoprecipitation, nuclear extracts of ESCs and EpiSCs were prepared and incubated with pre-bound 4 μg Zfp281 (Abcam, ab101318) or IgG (Millipore, PP64) antibodies with protein G-Agarose beads (\#11243233001, Roche) overnight at 4°C. Immunoprecipitates were washed five times with IP buffer, eluted from the beads by boiling, and separated by SDS-PAGE. Western blot analyses were carried out using the following primary antibodies: Zfp281 (sc-166933, Santa Cruz, RRID:[AB_10612046](https://scicrunch.org/resolver/AB_10612046)), Ep400 (Bethyl, A300-541A, RRID:[AB_2098208](https://scicrunch.org/resolver/AB_2098208)), Trrap (Santa Cruz, sc-5405, RRID:[AB_2209666](https://scicrunch.org/resolver/AB_2209666)), Chd4 (Abcam, ab70469, RRID:[AB_2229454](https://scicrunch.org/resolver/AB_2229454)), Mbd3 (Abcam, ab157464), Suz12 (Abcam, ab12073), Oct4 (Santa Cruz, sc-5279, RRID:[AB_628051](https://scicrunch.org/resolver/AB_628051)), and P300 (Santa Cruz, sc-584, RRID:[AB_2293429](https://scicrunch.org/resolver/AB_2293429)).

RT-qPCR {#s4-8}
-------

Total RNA was extracted from ESCs or EpiSCs using the RNeasy kit (Qiagen), and from E6.5 embryos using the TRIZOL reagent (Ambion, \#15596018). Reverse transcription was performed and cDNA was generated using the qScript kit (Quanta, Cat\# 95048). Relative expression levels were determined using a LightCycler 480 SYBR green mix (Roche, 4729749001). qRT-PCR experiments were performed on a LightCycler Real Time PCR System (Roche). Gene expression levels were normalized to Gapdh. Error bars indicate standard error for average expression of two technical replicates. Primers for qPCR are listed in [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}.

ChIP-qPCR {#s4-9}
---------

ChIP assays were performed as described ([@bib40]). Briefly, cells were cross-linked with 1% (w/v) formaldehyde for 10 min at room temperature, and formaldehyde was inactivated by the addition of 125 mM glycine. For embryo ChIP, the protocol was modified. Briefly, embryonic regions were dissected from 24 (Experiment\#1) or 25 (Experiment\#2) E6.5 WT embryos. After formaldehyde crosslinking and quenched by glycine, embryos were washed once with lysis buffer \#1, then resuspend in lysis buffer \#3 for sonication. Sonication was performed on a Bioruptor system, with 30 s ON, 30 s OFF, 30 cycles, high amplitude. Chromatin extracts containing DNA fragments were immunoprecipitated by incubating with primary antibody-conjugated DynaBeads (Novex, 10003D) overnight with rotation at 4°C. The immunoprecipitated DNA was purified with ChIP DNA Clean and Concentrator columns (Zymo Research), analyzed by qPCR using Roche SYBR Green reagents and a LightCycler480 machine, and percentage of input recovery was calculated. Error bars indicate standard error for average expression of two technical replicates. The primary antibodies used for ChIP: Zfp281 (Abcam, ab101318, RRID:[AB_11157929](https://scicrunch.org/resolver/AB_11157929)), H3K27ac (Abcam, ab4729, RRID:[AB_2118291](https://scicrunch.org/resolver/AB_2118291)), H3K27me3 (Millipore, 07--449, lot 2194165, RRID:[AB_310624](https://scicrunch.org/resolver/AB_310624)), Suz12 (Active Motif, \#39357, RRID:[AB_2614929](https://scicrunch.org/resolver/AB_2614929)), and IgG (Millipore, PP64, RRID:[AB_97852](https://scicrunch.org/resolver/AB_97852)). The primers used for qPCR are listed in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"} *and [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}*.

RNA-seq analysis of embryos {#s4-10}
---------------------------

Mouse embryos were dissected at E6.5 and total RNAs were extracted using TRIZOL reagent (Ambion, \#15596018) following standard protocols. RNA quality was evaluated with an Agilent 2100 BioAnalyzer system, and embryo genotype was determined by morphology and confirmed by expression of *Zfp281* by RT-qPCR. Ten to one-hundred ng total RNA from each embryo was processed for RNA-seq library construction using the Ovation Mouse RNA-seq kit (NuGEN, \#0348--32) following the manufacturer's protocol, then massively parallel sequencing was performed on an Illumina HiSeq 4000 Sequencing System. Between 20 and 50 million 100 bp single-end reads were obtained per sample.

RNA-seq reads were aligned to the genome using TopHat (v2.0.10) and Bowtie2 (v2.1.0) with the default parameter settings. UCSC mm9 mouse genome, as well as the transcript annotation, was downloaded from the iGenomes site. Transcript assembly and differential expression analyses were performed using Cufflinks (v2.1.1). Assembly of novel transcripts was not allowed (-G), other parameters of Cufflinks followed the default setting. The summed RPKM (reads per kilobase per million mapped reads) of transcripts sharing each gene_id were calculated and exported by the Cuffdiff program. In the RPKM data matrix, a minimal RPKM value of 0.1 was applied if gene expression was less than this minimal value. P-values were calculated using T-test.

RNA-seq data of WT and *Zfp281*KO ESCs and EpiLCs from our previous study (accession: GSE81042) were processed with the same settings.

Gene Ontology (GO) analysis {#s4-11}
---------------------------

Gene ontology analyses were performed using the DAVID gene ontology functional annotation tool (<http://david.abcc.ncifcrf.gov/tools.jsp>) with all NCBI Mus musculus genes as a reference list.

Geneset enrichment analysis (GSEA) {#s4-12}
----------------------------------

GSEA (v2.1.0, available at <http://www.broadinstitute.org/gsea>) was used to determine whether the set of genes of interest was statistically enriched in *Zfp281*KO versus WT embryo RNA-seq data. The genesets used for this study were derived from the Reactome pathway database. The enrichment plot, normalized enrichment score (NES) and q-value (FDR) were indicated for each enrichment test.

ChIP-seq analysis {#s4-13}
-----------------

ChIP was performed as previously described ([@bib40]) using a Zfp281 antibody (Abcam, ab101318) in EpiSCs. ChIP-seq data of Zfp281 in ESCs were from our previous data set at GEO (accession: GSE81042). Massively parallel sequencing was performed with the Illumina HiSeq 2500 Sequencing System according to the manufacturer's protocol. All libraries were sequenced as 100 bp single-end reads. ChIP-seq raw data were processed as previously described ([@bib29]). Briefly, reads were aligned to the mouse genome (NCBI build 37, mm9) using the Bowtie (v1.0.0) program, with parameters -m 1. The aligned reads were sorted, and duplicated reads were removed using samtools (v0.1.19). BAM files were converted to a binary tiled file (tdf), and visualized using IGV (v2.3) software.

Zfp281 ChIP-seq peaks were determined using the MACS2 program (v2.0.10) with input ChIP-seq as the control. MACS2 parameters followed the default settings. Zfp281 ChIP-seq peaks were annotated using the annotatePeaks module in the HOMER program (v4.6) against the mm9 genome. Overlap of Zfp281 ChIP-seq peaks in ESCs and EpiSCs was determined by Bedtools (v2.18.1). The diffbind package (available from <http://bioconductor.org/>, v1.16.3) was used to determine the ChIP-seq intensities (by aligned reads per million total reads, RBM) of Zfp281 peaks.

Public ChIP-seq data were downloaded from GEO, and processed with the same settings. Colocalization of Zfp281 and other transcription and epigenetic factors (see accessions in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}) was performed with an in-house Python (v2.7.6) program as previously described ([@bib22]). Briefly, ChIP-seq reads were downloaded and processed to determine a peak list by MACS2. A phi correlation coefficient was used to calculate the correlation between the peak lists of every two ChIP-seq data. Heatmap of correlations was shown with the TreeView program.

Accession number {#s4-14}
----------------

Zfp281 ChIP-seq data and *Zfp281*KO embryo RNA-seq data are available in GEO under accession GSE93044.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"Zfp281 is essential for epiblast maturation through transcriptional control of Nodal Signaling in the mouse embryo\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

You will see that two of the reviewers are positive and we do not disagree with the positive comments of our fellow reviewers. However, we do not think that a description of a mouse gastrulation phenotype is sufficient for publication in a high profile journal today. Our particular concern with this paper is that both parts are incomplete and are being forced together to fit a particular interpretation which may be only partly correct or even completely incorrect. To summarise briefly: the authors are working on a gene of interest in embryonic stem cell biology and here they describe a requirement for proper axis formation and gastrulation. Based on altered expression patterns in the mutant embryos they attribute this phenotype to disruption of Nodal signalling. They then provide genome location data indicating that potentially Zfp281 might regulate Nodal directly. So far, so good. What they do not go on to provide is direct evidence that Nodal or Nodal signalling are perturbed either in the embryo prior to overt phenotype manifestation or in the in vitro ES cell system. Nor do they determine which effects are cell autonomous in the epiblast. This is central to their argument that Zfp281 drives pluripotency progression. The missing experiments are straightforward for investigators of this experience and expertise and in would be expected by any developmental or stem cell biology journal and general interest journal too.

Reviewer \#1:

The transcription factor Zfp281 was recently shown to be a key regulator of primed pluripotency in vitro (Fidalgo et al., 2016). In this manuscript, the Wang group focuses on the role of Zfp281 in vivo, elegantly and comprehensively describing a critical requirement for Zfp281 during the earliest stages of mouse post-implantation development.

Between the pre-implantation and early post-implantation periods, Zfp281 expression resolves from a broader distribution within the blastocyst (all 3 lineages) to the egg cylinder epiblast. (There is pesky background staining with their antibody in the visceral endoderm in [Figure 1](#fig1){ref-type="fig"}.) The authors next derive mice from a previously published mutant Zfp281 mouse ES cell line (Fidalgo 2011 Stem Cells). Zfp281 homozygous embryos are morphologically distinct from their WT littermates by E6.5, with a thickened distal visceral endoderm and smaller size, and do not survive beyond embryonic day (E) 8.0. Thus, the authors performed comparative RNA-seq on whole wild-type and Zfp281-/- E6.5 embryos in an effort to identify the gene networks dysregulated by loss of Zfp281. The most significantly downregulated genes in Zfp281 mutants were prominent components of the Nodal signaling pathway (e.g., Nodal itself, Foxh1, Lefty1/2) as well as genes that display specific spatiotemporal expression domains in the epiblast such as the posterior primitive streak or visceral endoderm. Posterior primitive streak markers (e.g., Fgf8, T/Bra, Nodal, Eomes) showed a \"radialized\" expression pattern by whole-mount, that is, situated proximally in the epiblast abutting the extraembryonic ectoderm. Consistent with this finding, AVE markers were rarely expressed, or only expressed at low levels in the distal visceral endoderm, which fails to migrate anteriorly. Taken together these findings indicate a failure to establish the primary anterior-posterior axis, suggesting that Zfp281 mutant embryos are stuck at the precipice to axis and lineage specification.

To determine those genes directly bound and regulated by Zfp281, the authors turned to an in vitro model of naïve (ESC) and primed (epiblast-like cells, EpiLC) pluripotency and performed Zfp281 ChIP-seq. Interestingly, the promoters of lineage-specific genes, which are typically expressed at higher levels in primed cells (EpiLC and EpiSC) than ESC ([Figure 5A](#fig5){ref-type="fig"}), were bound by Zfp281 with greater enrichment in ESC than in EpiLC ([Figure 5B,C](#fig5){ref-type="fig"}). The authors interpret these findings to mean that Zfp281 regulates lineage-specific genes during epiblast \"maturation.\" They next combined their Zfp281 ChIP-seq data with publically available binding data sets for epigenetic regulators and transcription factors. Zfp281, Ep400 and the PRC2 components Ezh2 and Suz12 have the most similar binding patterns, with Zfp281/Ep400 and Suz12 co-binding observed at bivalent genes marked by co-enrichment of active H3K4me3 and repressive H3K27me3. During the transition from naïve to primed pluripotency, the authors propose that there is a reduced association between Zfp281 and the PRC2 complex at bivalent promoters, resulting in decreased H3K27me3 and transcriptional activation of lineage-specific genes. Lastly, the authors revisit the role of Zfp281 and transcriptional activation of the Nodal locus and determine that Oct4 and P300 collaborate with Zfp281 to activate Nodal and is components Foxh1 and Lefty2 during epiblast \"maturation.\" Their findings support a model of enhancer switching from HBE to ASE as the epiblast exits pluripotency.

This reviewer finds the present work to be both comprehensive and insightful, certainly meriting publication in *eLife* and highlighting the importance of in vivo studies to more fully understand the role of Zfp281 previously described only in vitro.

Reviewer \#2:

In this manuscript, Huang et al. characterise the function of the zinc finger protein, Zfp281, in early mouse development during exit from pluripotency, axis specification and lineage priming. Zfp281 was previously identified from ES cell screening as a potential candidate for facilitating differentiation in vitro. The authors provide a detailed analysis of the expression profile of Zfp281 in mouse embryos at significant stages around the time of implantation and gastrulation, including quantification of levels of fluorescence. They show enriched expression in the epiblast from E4.25 until early postimplantation. The knockout phenotype begins very soon after implantation, with a thickening of the visceral endoderm and reduced proliferation of the epiblast. Thereafter, the mutant embryo lacks anterior-posterior patterning with no evidence of gastrulation, explaining the absence of homozygous null embryos from E8.5. Using gene expression profiling of null versus wild type embryos the authors identify Nodal as the most affected signalling pathway in mutant embryos, with Nodal itself and its downstream targets being underrepresented in null embryos by E6.5. As expected, the perturbation of the Nodal pathway affects the anterior-posterior patterning of mutant embryos and prevents specification of the primitive streak. This was manifested by mis-regulation of Nanog, T, Eomes, FGF8, Axin2, Otx2 and Sox2, even though their total expression levels were largely unaffected. Many of the known anterior markers were lost or disrupted in mutant embryos. This explains the encroachment of primitive streak genes to the anterior epiblast in mutant embryos.

To address the mechanism of Zfp281 activity during exit from naïve pluripotency the authors used EpiLCs generated after 2 days culture of ES cells in EpiSC conditions. They used ChIP-seq to show that Zfp2981 is enriched at regulatory regions of multiple genes with both conservation and divergence between ES cells and EpiLCs, implying a dynamic role during differentiation. In particular, Zfp281 bound to early lineage genes in ES cells. Interestingly, only the enhancers and not the promoters of FGF5 and 8 were bound by Zfp281, implying both promoter dependent and independent mechanisms for its action. Zfp281 associates with specific sets of epigenetic regulators, which differ between ES cells and EpiSCs. There was also reduced chromatin occupancy at bivalent promoters for T and Eomes in mutant compared with wild type ES cells. The authors suggest that Zfp281 is actively involved in reduction of H2K27me3 during exit from pluripotency. Nodal enhancer activity was explored in ES cells and EpiSCs and confirmed to be dynamic during the transition from naïve to primed pluripotency in vitro. Direct evidence for the mechanism of action of Nodal during lineage priming in vivo was obtained by performing ChIP experiments on wild type E6.5 embryos. Zfp281 binding was observed in regulatory regions of Nodal and some of its targets affected in mutant embryos.

This study is beautifully planned, executed and presented with sufficient novel and interesting findings to enhance understanding of the mechanism of exit from pluripotency and lineage priming and the role of Nodal signalling during this process in vivo and in vitro.

Reviewer \#3:

In this paper Huang et al. first describe the early lethality in mouse embryos deficient for Zfp281 and then apply ChIP-seq in ES cells and EpiSCs. Previous studies from Jianlong Wang have implicated Zfp281 in regulation of both ES cell self-renewal and early differentiation. Given a strong in vitro effect on ES cell differentiation there is interest in elucidating the stage, character and causality of the in vivo phenotype. In the present study the authors infer a relationship with Nodal signalling in early embryogenesis and suggest that Zfp281 lies directly upstream of Nodal itself. This would be very interesting, if proven. The latter section of the paper, comprising genome-wide analyses in ES cells and EpiSCs, is only loosely connected to the embryo phenotype and doesnot provide mechanistic data. Overall, neither component in the study is taken through to completion and the whole is rather less than the sum of the parts. In the end we are still little wiser as to the functional role and mode of action of Zfp281 in either embryonic development or ES cell differentiation.

The first section of the paper reports a gastrulation stage phenotype in Zfp281 null embryos and notes common features with Nodal mutants. This work is well done and the results are clearly presented and described. However, the study is incomplete. If the phenotype is attributed to dysregulation of the Nodal pathway we need to know whether expression of Nodal components is indeed disrupted prior to the overt phenotype, i.e. at E5.5. More generally, phenotypic analysis of the peri-implantation period is critical for the central argument of the paper that Zfp281 drives progression from naïve pluripotency. Are genes that are up-regulated early in transition, such as Otx2 and Pou3f1, expressed correctly or not in mutant embryos at E5.5? Conversely, it is necessary to determine whether the epiblast defects are indeed cell-autonomous, as the authors argue, or are entirely secondary to failure of the DVE and subsequent absence of AVE. Tetraploid blastocyst complementation is well-established as the method to address this issue. Alternatively the authors could create an epiblast-specific deletion using Sox2::Cre or other suitable driver. These experiments will take time, but frankly without them the present description does not allow any conclusions as to the primary defect and cell autonomous versus non-autonomous action. The RNA-seq analyses appear to have been carried out on whole embryos. Validation by ISH or IF to confirm tissue/region, at least for up-regulated genes such as AFP, would be expected.

The second part of the paper features molecular analyses in vitro. The authors present correlations from ChIP-seq analyses but they do not test directly any of the inferences. The key advantage of in vitro stem cell systems is that they enable not just high throughput data collection but also direct and rigorous examination of hypothesised regulatory interactions. Unfortunately there is no such test of what I take to be the main hypothesis, that Zfp281 directly regulates Nodal expression and Nodal signalling. Is Smad2/3 phosphorylation affected in the mutants? To what extent is the Zfp281 phenotype recapitulated by inhibition and/or genetic ablation of nodal signalling. The authors report that gene expression is perturbed in EpiLCs but the protocol for generating EpiLCs involves addition of activin, so should not be affected by diminished nodal expression.

Previous reports from the Wang lab have asserted that Zfp281 acts via Nanog and NuRD and most recently Tets. The current manuscript claims further modes of action; interaction with Tip60-Ep400m, and direct regulation of Nodal and nodal pathway components. But how are these different mechanisms integrated and what is their relative significance. The study does not provide any coherent synthesis. Simply saying Zfp281 is a master regulator is not really sufficient. We are left with insufficient clarity as to how and when Zfp281 is required in vitro or in vivo.

10.7554/eLife.33333.050

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> \[...\] This reviewer finds the present work to be both comprehensive and insightful, certainly meriting publication in eLife and highlighting the importance of in vivo studies to more fully understand the role of Zfp281 previously described only in vitro.

We thank this reviewer for his/her comments which are both supportive of publication of our manuscript in *eLife*, as well as recognizing the significance of this work, and the importance of undertaking in vivoand in vitrostudies to fully understand the function of Zfp281.

> Reviewer \#2:
>
> \[...\] This study is beautifully planned, executed and presented with sufficient novel and interesting findings to enhance understanding of the mechanism of exit from pluripotency and lineage priming and the role of Nodal signalling during this process in vivo and in vitro.

We thank this reviewer for his/her positive and supportive comments on the planning and execution of our study, and the significance of our findings.

> Reviewer \#3:
>
> In this paper Huang et al. first describe the early lethality in mouse embryos deficient for Zfp281 and then apply ChIP-seq in ES cells and EpiSCs. Previous studies from Jianlong Wang have implicated Zfp281 in regulation of both ES cell self-renewal and early differentiation. Given a strong in vitro effect on ES cell differentiation there is interest in elucidating the stage, character and causality of the in vivo phenotype. In the present study the authors infer a relationship with Nodal signalling in early embryogenesis and suggest that Zfp281 lies directly upstream of Nodal itself. This would be very interesting, if proven.

We appreciate the reviewer\'s interest in our work. However, we want to clarify that our data, for example our in vitroand in vivoChIP-qPCR experiments presented in [Figure 7D-E](#fig7){ref-type="fig"}, support the direct binding of Zfp281 on the *Nodal* promoter during epiblast maturation. Ours is the first study to demonstrate direct in vivobinding at the *Nodal* locus. We would therefore argue that we do not *per se* infer a role for a relationship between Zfp281 and Nodal signaling. Our suggestion of Zfp281 lying upstream of Nodal comes from direct experimental evidence (binding of Zfp281 to *Nodal cis-*regulatory elements in vitroin pluripotent stem cell models, and in vivoin embryos) provided in our manuscript.

We would also like to point out the two other reviewers of our manuscript also noticed these data, and commented that \"Their findings support a model of enhancer switching from HBE to ASE as the epiblast exits pluripotency\" (Reviewer 1) and \"Zfp281 binding was observed in regulatory regions of Nodal and some of its targets affected in mutant embryos.\" (Reviewer 2).

> The latter section of the paper, comprising genome-wide analyses in ES cells and EpiSCs, is only loosely connected to the embryo phenotype and doesnot provide mechanistic data. Overall, neither component in the study is taken through to completion and the whole is rather less than the sum of the parts. In the end we are still little wiser as to the functional role and mode of action of Zfp281 in either embryonic development or ES cell differentiation.

We respectfully disagree with the reviewer\'s comment that the in vitro and embryo data are \"only loosely connected\", as both sets of experiments cross-reference one another and have cross-confirmatory findings. These correlative in vitro and in vivo studies together forged the link to Nodal signaling, which was confirmed by performing technically challenging ChIP-qPCR experiments on embryos. We would also like to point out that our present study is one of the first to demonstrate direct binding of a transcription factor to cis-regulatory elements in vivo in mouse embryos.

We believe that the reviewer\'s comment that our genome-wide analyses in ES cells and EpiSCs do not provide mechanistic data explaining the embryo phenotype was unfair and unjustified. The in vitro ESC-to-EpiSC differentiation system coupled with genome-wide analyses have been widely applied in providing mechanistic understanding of transcriptional and epigenetic regulation underlying naïve-to-primed pluripotency transition (work from the Surani, Wysocka, Smith labs, as well as our own previous work).

Perhaps the most pertinent example is a study from Austin Smith\'s laboratory (Cambridge, UK), recently published in the journal Stem Cell Reports (Mulas et al., 2017), in which the authors utilized an in vitro ESC-to-EpiSC model and uncovered a role for Nodal in securing pluripotency upon ESC progression from the ground state. Importantly, in their Discussion, Mulas et al. concluded that \"Our findings point to a pivotal role for NODAL signaling in establishing formative pluripotency, in keeping with observations of a requirement for continuous NODAL activity to sustain pluripotency in the early postimplantation epiblast\".

Similarly, we have also provided a careful discussion in our manuscript for how our in vitro findings may offer mechanistic insights into molecular control underlying the early postimplantation epiblast, and transitions between pluripotent states. More importantly, our data supports a model whereby Zfp281 directly binds the Nodal promoter during epiblast maturation (as shown by both our in vitro and in vivo ChIP-qPCR data in [Figure 7D-E](#fig7){ref-type="fig"}), and that Nodal expression is affected by loss of Zfp281 in the embryo. We also show the direct regulation by Zfp281 of genes that need to be activated for the epiblast to properly mature.

We have added more data, as detailed below, to strengthen the statements made and hypotheses arising from our work.

> The first section of the paper reports a gastrulation stage phenotype in Zfp281 null embryos and notes common features with Nodal mutants. This work is well done and the results are clearly presented and described.
>
> However, the study is incomplete. If the phenotype is attributed to dysregulation of the Nodal pathway we need to know whether expression of Nodal components is indeed disrupted prior to the overt phenotype, i.e. at E5.5. More generally, phenotypic analysis of the peri-implantation period is critical for the central argument of the paper that Zfp281 drives progression from naïve pluripotency. Are genes that are up-regulated early in transition, such as Otx2 and Pou3f1, expressed correctly or not in mutant embryos at E5.5?

We agree with the reviewer that these data on earlier embryos would strengthen our manuscript and support our conclusions. We have now included ISH/immunostaining for the suggested markers at earlier stages: additional IFs are added in [Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"} to strengthen our conclusions that markers of the formative state (Otx2 and Oct6/Pou3f1) are downregulated in *Zfp281*KO embryos before migration of the AVE/DVE and after the embryo\'s implantation (E5.5). To our knowledge, Oct6 protein distribution at this stage has never been published (only WISH data were published at early post-implantation (Zhu et al., 2014) or by RNA-seq of E5.5 embryos (Kalkan et al., 2017) and as noted in [Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}, seems to be quite mosaic in embryos.

We also added WISH for Nodal at E5.5 in [Figure 4---figure supplement 2E](#fig4s2){ref-type="fig"}, showing that its expression is already downregulated in E5.5 *Zfp281*KO embryos when compared to WT.

> Conversely, it is necessary to determine whether the epiblast defects are indeed cell-autonomous, as the authors argue, or are entirely secondary to failure of the DVE and subsequent absence of AVE. Tetraploid blastocyst complementation is well-established as the method to address this issue. Alternatively the authors could create an epiblast-specific deletion using Sox2::Cre or other suitable driver. These experiments will take time, but frankly without them the present description does not allow any conclusions as to the primary defect and cell autonomous versus non-autonomous action.

Unfortunately, at present there is no conditional allele available for *Zfp281* so the epiblastspecific ablation is not currently possible. The mouse *Zfp281* locus has a very unusual structure that does not make it easily amenable to conditional mutagenesis. As an alternative approach to assessing the epiblast-specific function of Zfp281, and as suggested by the reviewer, we have generated 4n (tetraploid) wild-type embryo \<-\> *Zfp281* mutant ESC chimeras. In such a tetraploid complementation experiment, the 4n tissues (extra-embryonic Primitive Endoderm and Trophectoderm derivatives) are wild-type, whereas all epiblast derivatives are *Zfp281* mutant. This, in principle, is an analogous experiment to an epiblast-specific deletion of a conditional mutant allele.

These 4n blastocyst complementation experiments have allowed us to clarify the epiblast specificity of Zfp281, and in doing so extend and support the immunofluorescent localization data presented in our original submission.

In accordance with our model, 4n wild-type embryo \<-\> *Zfp281* mutant ESC chimeras recapitulate the *Zfp281* null mutant phenotype.

· 4n Zfp281KO ESC chimeric embryos exhibit thickened VE layer similarly to Zfp281KO embryos (added in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}).

· As in *Zfp281*KO embryos, some pluripotency associated markers are also downregulated in *Zfp281*KO ESC chimeras at E5.75-6.0 (added in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

· We note that *Zfp281*KO ESC chimeras exhibit a failure to establish the anterior-posterior axis (added in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

· 4n Zfp281KO ESC chimeric embryos exhibit the same pattern of expression of Nanog and T as Zfp281KO embryos at E7.25 ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}).

· Furthermore, we go on to show that 4n wild-type embryo \<-\> cDNA rescued Zfp281 mutant ESC chimeras exhibit a partial rescue of the *Zfp281* mutant phenotype.

In conclusion, these new 4n (tetraploid complementation) chimera data support our proposed model for Zfp281 exhibiting a cell autonomous function within the epiblast, which was originally based on our demonstration of Zfp281 being exclusively expressed within the epiblast at the time of implantation (and thereafter).

Importantly, these 4n chimera data (and neither an epiblast-specific ablation using a conditional allele) will not allow us to answer the question as to whether the defects we observe are due to a failure of DVE/AVE specification and/or migration. We would argue that experiments addressing this question are beyond the scope of the present study.

> The RNA-seq analyses appear to have been carried out on whole embryos. Validation by ISH or IF to confirm tissue/region, at least for up-regulated genes such as AFP, would be expected.

We have already provided validation of RNA-seq data by ISH or IF for a number of downregulated genes in our manuscript. For up-regulated genes such as Afp as suggested, however, a working antibody for AFP IF is lacking. We nonetheless performed additional RT-qPCR on embryos and confirmed their up-regulation for a number of genes (data are added in [Figure 2D](#fig2){ref-type="fig"}) and have added more explanations and discussion (paragraph two) in our revised manuscript.

> The second part of the paper features molecular analyses in vitro. The authors present correlations from ChIP-seq analyses but they do not test directly any of the inferences. The key advantage of in vitro stem cell systems is that they enable not just high throughput data collection but also direct and rigorous examination of hypothesised regulatory interactions. Unfortunately there is no such test of what I take to be the main hypothesis, that Zfp281 directly regulates Nodal expression and Nodal signalling. Is Smad2/3 phosphorylation affected in the mutants? To what extent is the Zfp281 phenotype recapitulated by inhibition and/or genetic ablation of nodal signalling. The authors report that gene expression is perturbed in EpiLCs but the protocol for generating EpiLCs involves addition of activin, so should not be affected by diminished nodal expression.

In accordance with the reviewer's comments, the following additional experiments were performed to dissect the functional connection between Zfp281 and Nodal signalingin vitroin ESCs and differentiation.

Firstly, we determined the level of phospho(p-)Smad2 in WT and *Zfp281*KO ESCs. As shown in our new [Figure 7A, p](#fig7){ref-type="fig"}-Smad2 intensity in *Zfp281*KO ESCs was significantly diminished compared to that observed in WT ESCs.

We previously demonstrated that endogenous Zfp281 is required for survival of EpiSCs or longterm culture of EpiLCs in primed conditions containing Activin (Fidalgo et al., 2016), suggesting that Zfp281 is important for the integrity of Nodal signaling. In this regard, we examined levels of p-Smad2 in EpiSCs with Zfp281 knockdown. As shown in the new [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}, knockdown of Zfp281 didn't change p-Smad2 activity in EpiSCs, probably because of the Activin in culture constitutively activates p-Smad2. However, we did observe that the expression of Lefty (using an antibody detecting both Lefty1/2) significantly decreased. This is in accordance with our ChIP-qPCR results that Zfp281 binds to *Lefty2* enhancer in in vitro ESCs/EpiSCs and in vivo E6.5 embryos ([Figure 7D, G](#fig7){ref-type="fig"}).

Furthermore, we treated ESCs and EpiSCs with ALK receptor inhibitor (ALKi) specifically diminishing Smad2/Nodal signaling. As shown in the new [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"} (copied below), ALKi treatment significantly reduces pSmad2 and Lefty expression.

In summary, our new data further demonstrated the functional role of Zfp281 in regulating Nodal signaling, particularly in EipSCs with Nodal signaling activation, Zfp281 is required to transcriptionally activate Nodal and downstream target *Lefty* in vitro ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}, [Figure 7](#fig7){ref-type="fig"}).

To further understand the functional significance of Zfp281 in controlling the Nodal signaling pathway during embryonic development, we employed the following four in vitrodifferentiation models that relate to Activin/Nodal signaling: ([@bib1]) ESCs to EpiLCs; ([@bib2]) ESCs to primitive streak (PS)-like cells; ([@bib3]) ESCs to definitive endoderm (DE)-like cells; and ([@bib5]) ESCs to PGCLCs.

1\) With Fgf2 and Activin, ESCs can differentiate into EpiLCs representing a subsequent stage of pluripotency, and we have previously shown that *Zfp281*KO is not compatible with the longterm culture of EpiLCs (Fidalgo et al., 2016).

2\) It is reported that Activin and GSK3β inhibitor (CHIR) promote differentiation of ESCs to primitive-streak (PS)-like cells (Tsakiridis et al., 2014). We therefore tested the role of Zfp281 in this differentiation. As shown in new [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}, we treated ESCs with Activin/CHIR, and with ALKi or Zfp281 shRNAs. Morphology of Zfp281 knockdown cells indicated a strong phenotype of differentiation resistance, which resembles that of ALKi treatment. Dome-shaped ESC-like colonies persisted in Zfp281 KD cells after Activin/CHIR treatment; a striking difference compared to control cells. RT-qPCR at different time points after treatment also indicated that the Zfp281 KD cells reproduced Nodal signaling inhibition by ALKi in terms of the expression of the PS marker gene *T* and the Nodal target gene *Lefty2* (expressed in PS).

3\) Activin/Nodal activity is required forin vitro differentiation of ESCs to definitive endoderm (DE)-like cells. According to a protocol developed by Gouon-Evans et al. (Gouon-Evans et al., 2006), DE differentiation starts within 2-days of embryonic body (EB) formation (Day2) in serumfree medium, then followed by additional 2\~3 days (Day4\~Day5) of Activin/Nodal activation. We first confirmed that WT ESCs (J1, CJ7) can form DE-like cells in our hands, indicated by robust activation of DE marker *Foxa2*. We then performed DE differentiation of *Zfp281*KO ESCs. At Day 2 of EB formation, similar percentages of live cells were obtained, indicating that Zfp281 is dispensable in forming EBs as we previously reported (Fidalgo et al., 2011). However, significant cell death was observed upon DE differentiation (Day4\~Day5) (Huang et al., manuscript under preparation). Since DE is a descendant lineage of epiblast, these data suggest that the failure of *Zfp281*KO ESCs to differentiate into DE may be due to an overall requirement for Zfp281 in epiblast development, which is consistent with the failure of *Zfp281*KO ESC in the ESC-to-EpiSC transition.

4\) A recent study from Austin Smith's lab (Cambridge, UK) has reported a role for Nodal signaling in differentiation of ESCs to Primordial Germ Cell Like Cell (PGCLC) (Mulas et al., 2017). Following the protocol of PGCLC differentiation from Mitinori Saitou's lab (Hayashi et al., 2011), we firstly adapted WT and *Zfp281*KO ESCs in 2iL (2i+LIF) conditions for 2 passages (\>10 days), followed by 2 days of EpiLC differentiation, and 4 days in conditions promoting PGCLC formation. Both WT and *Zfp281*KO cells can form PGCLCs. By assaying the mRNA expression of PGC markers (*Nanos3, Stella, Tfap2c, Nanog, Prdm1, Prdm14*), we found that these genes generally followed a similar trend in PGCLC differentiation. Moreover, we observed that many of them exhibited higher levels of expression in *Zfp281*KO cells compared to WT cells, in the initial 2iL naive ESC state and the final PGCLC state ([Author response image 1](#respfig1){ref-type="fig"}).

These data differ from Smith's results in which inhibition of Nodal signaling led to a reduction in the expression of PGC marker genes. However, since Activin is not used in the standard PGCLC differentiation protocol, it is still not clear how Nodal signaling can contribute to PGCLC formation. Furthermore, Mulas et al. indicated Activin treatment can rescue the Nodal KO phenotype in PGCLC formation, and speculated that expression of Gdf3, a Vg-1 homolog, may elicit a Nodal-like response (Mulas et al., 2017). In our experiments, we find PGC markers to also be expressed in naive ESCs, and we previously showed these naive markers (Nanog, Stella, Prdm14) are repressed by Zfp281 in 2iL ESCs (Fidalgo et al., 2016). These observations may, at least in part, explain the higher levels of PGC marker genes observed in *Zfp281*KO cells.
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Thus, in our attempts to answer the reviewer's question "To what extent is the Zfp281 phenotype recapitulated by inhibition and/or genetic ablation of nodal signaling", we applied multiple in vitro differentiation protocols (EpiLC, PS, DE) from WT/*Zfp281*KO ESCs especially in contexts in which Activin/Nodal signaling is essential for the respective differentiation. We also showed *Zfp281* KD can reproduce Nodal signaling inhibition in terms of cell morphology change upon differentiation and expression of Nodal signaling targets. However, we did not directly test the outcome of *Nodal* KO because the function/requirement of/for Nodal has been well-studied in many of these contexts, and is outside the scope of our present study. Furthermore, even with *Nodal* KO cells, it has been reported that Nodal signaling is unaffected upon Activin treatment with respect to the expression of pathway target genes, for example *Lefty2* (Mulas et al., 2017).

In our revised manuscript, we provide these additional in vitro ES cell differentiation data to support our hypothesis that Zfp281 is required for maintaining the integrity of Nodal signaling in in vitro ESC differentiation models. For DE differentiation, it is still unclear why *Zfp281*KO cells fail to differentiate and instead exhibit massive cell death/apoptosis. For the ESC-to-PGCLC differentiation paradigm, we believe that the function of Nodal signaling remains ill-defined, and thus we decided not to include our DE and PGCLC data in the revised manuscript.

> Previous reports from the Wang lab have asserted that Zfp281 acts via Nanog and NuRD and most recently Tets. The current manuscript claims further modes of action; interaction with Tip60-Ep400m, and direct regulation of Nodal and nodal pathway components. But how are these different mechanisms integrated and what is their relative significance. The study does not provide any coherent synthesis. Simply saying Zfp281 is a master regulator is not really sufficient. We are left with insufficient clarity as to how and when Zfp281 is required in vitro or in vivo.

In this study, we focus on the function of Zfp281 within the epiblast of the early post-implantation mouse embryo, and comparablein vitroexit from pluripotency and concomitant lineage gene specification. In this way, the present study is complementary to, and indeed significantly extends, our previous knowledge on Zfp281 in pluripotency (Fidalgo et al., 2012; Fidalgo et al., 2016; Fidalgo et al., 2011). In the present study we uncover two regulatory machineries in which Zfp281 has a central and critical role: Zfp281/PRC2/Ep400 on Class I (bivalent) genes, and Zfp281/PRC2/Ep400 on Class II (pluripotency) genes ([Figure 6B, C](#fig6){ref-type="fig"}). We have shown Zfp281 is a repressor for pluripotency-associated genes (through NuRD) in ESCs (Fidalgo et al., 2012), we therefore focused on the role of Zfp281 on bivalent/lineage specific genes in this work. Specifically, as we state in our manuscript: \"The lack of association between Zfp281 and NuRD in EpiSCs may also explain why pluripotency genes including *Sox2* and Nanog are not regulated by Zfp281 in the epiblast ([Figure 3A, D](#fig3){ref-type="fig"}), which is in contrast with NuRD-mediated Nanog repression in ESCs due to their physical association (Fidalgo et al. 2012).\"

In our (E6.5) embryo qPCR ([Figure 2D](#fig2){ref-type="fig"}) and immunofluorescent staining ([Figure 3A, D](#fig3){ref-type="fig"}) data, we report no difference in Nanog expression between WT and *Zfp281*KO embryos, therefore we did not go on to further investigate Nanog as a target of Zfp281 at post-implantation stages. For the TET proteins, previously we showed that Zfp281 represses *Tet2* expression, but has no effect on *Tet1* (Fidalgo et al., 2016). As shown in [Author response image 2](#respfig2){ref-type="fig"}, qPCR of E6.5 embryos indicated Tet1 is the highest expressed TET gene at this stage, while Tet2 exhibits highly reduced expression. We confirmed that Tet1 expression is not affected in *Zfp281*KO embryos, whereas Tet2 is appreciably upregulated. Moreover, Zfp281 physically interacts with Tet1 (but not Tet2), suggesting Zfp281/Tet1 may have similar function on their target genes (Fidalgo et al., 2016). Previously, Anjana Rao's group (La Jolla, USA) reported that Tet1 is required for the demethylation of the *Lefty1* promoter in ESCs (Koh et al., 2011). More recently, a study from Guoliang Xu's group (Shanghai, China) suggested that TET proteins are essential for the demethylation of *Lefty* promoters in vivo before the onset of gastrulation (Dai et al., 2016). Both these studies are supportive of our data reporting Zfp281 as an upstream regulator of the Nodal signaling pathway. The fact that Zfp281 is a key transcription factor that can not only coordinate the opposing functions of Tet1 and Tet2 during the naive-to-primed transition in vitro (Fidalgo et al., 2016), but also directly bind and control *Nodal* enhancer elements justifies referring to it as a master regulator.
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Thus, we have provided explanations/coherent synthesis on these different mechanisms and their relative significance. In the revised manuscript, we have placed increased emphasis on the published work from other groups as well as ourselves, further clarifying a central and comprehensive role for Zfp281 in embryonic development (last paragraph of Discussion).
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